Novartis has said it will pay $245 million to resolve civil litigation in the US, which accuses it of a 'pay for delay' scheme involving generics of its high blood pressure therapy Exforge.

This leaflet answers some common questions about Exforge HCT. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. The information ...

It is projected by analysts that the 'Revenues- Established Brands- Exforge Group - US' will reach $3.54 million. The estimate indicates a change of -11.6% from the prior-year quarter. Analysts ...

For example, Novartis' Exforge (amlodipine and valsartan) is forecast to have revenues above US$600 million in the seven major markets (France, Germany, Italy, Spain, UK, Japan and US) by 2012 ...

Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including Entresto ...

Novartis (NVS) reported $11.83 billion in revenue for the quarter ended March 2024, representing a year-over-year decline of 8.7%. EPS of $1.80 for the same period compares to $1.71 a year ago. The ...

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 34 of the Interim Financial Report. Unless otherwise noted, ...